Revolutionizing Healthcare: Ascentage Pharma Secures $126M in Funding for Cutting-Edge Therapies

Ascentage Pharma, a forward-thinking global biotechnology company headquartered in Suzhou, China, has successfully raised $126 million in its latest funding round, marking a significant milestone for the organization as it continues to drive innovation in oncology and chronic hepatitis B (CHB) treatment, as well as addressing senescent diseases. Established with a commitment to pioneering new therapies that target diverse molecular pathways regulating apoptosis, Ascentage Pharma has established itself as a clinical-stage leader with a robust pipeline of seven clinical drug candidates. By focusing on highly selective and potent Bcl-2 and dual Bcl-2/Bcl-xL inhibitors, alongside next-generation tyrosine kinase inhibitors that tackle treatment-induced resistance mutations, the company is poised to make substantial contributions to the medical community. This recent funding will enable Ascentage Pharma to accelerate its groundbreaking research and development efforts, expand its global clinical trials—which currently exceed 40 in various regions—and ultimately bring transformative therapies to patients in need. The successful listing on the Main Board of the Stock Exchange of Hong Kong Limited under stock code 6855.HK in 2019 has catalyzed the company's growth, and with this new influx of capital, Ascentage Pharma is on track to solidify its position at the forefront of biopharmaceutical innovation. As the battle against cancer and other chronic diseases intensifies, this funding will not only enhance the company’s ongoing projects but will also empower Ascentage Pharma to explore new horizons in the therapeutic landscape.